April 28, 2023 02:45 PM EDT

Otsuka and Lundbeck get FDA nod for schizophrenia, bipolar disorder injection

Katherine Lewin

News Reporter

The FDA approved a new long-acting drug for schizophrenia and bipolar disorder on Thursday, adding to the growing rank of drugs for the mental disorders …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Otsuka and Lundbeck get FDA nod for schizophrenia, bipolar disorder injection

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

WuXi companies may sell units impacted by Biosecure — report

Exclusive: Relay Therapeutics cuts another 10% of company, citing continued streamlining efforts

Flagship partners with key Singapore R&D agency as it boosts APAC investment

End of obesity drug shortage threatens patient access to compounded shots that Lilly calls risky

Eli Lilly resolves shortage for tirzepatide, potentially ending compounders' run

3 Tiers for AAV Potency Assay Development Success

Ot­su­ka and Lund­beck get FDA nod for schiz­o­phre­nia, bipo­lar dis­or­der in­jec­tion

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Otsuka and Lundbeck get FDA nod for schizophrenia, bipolar disorder injection